Specialty Pharma Division

Our Specialty Pharma Division is a neurology-focused, specialty pharmaceutical company, dedicated to developing products for unmet needs in the treatment of Central Nervous System (CNS) disorders and other specialty segments.

Experience in Neurology Research

The executive management team of Impax has extensive experience developing and marketing products for CNS disorders. The branded business is currently focused on internally developing CNS products where we can deliver meaningful patient benefits and develop strong intellectual property positions. The long-term strategy is to build a strong pipeline through both internal R&D and external business development.

Commercial CNS Products

In January, 2015 the U.S. Food and Drug Administration (FDA) approved RYTARY® (Carbidopa and Levodopa) Extended-Release Capsules is for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. RYTARY is not for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. For complete safety and full prescribing information for RYTARY, go to www.rytary.com.

In February 2012, we licensed from AstraZeneca the exclusive U.S. commercial rights to Zomig® (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations pursuant to the terms of the AZ Agreement and began sales of the Zomig® products under our label through our specialty sales force. As of May 2013, the specialty sales force has focused on the nasal spray following loss of exclusivity on the Zomig® tablet and ODT product.

Zomig® and Zomig-ZMT® are registered trademarks of the AstraZeneca group of companies and are exclusively licensed in the U.S. to Impax in connection with Impax’s commercialization of Zomig®. For more information about Zomig®, go to www.zomig.com.

Product Pipeline

The Company’s leading brand R&D product is IPX203, a new extended-release oral capsule formulation of carbidopa and levodopa (CD-LD), as a potential treatment for symptoms of Parkinson’s disease. The Company is currently enrolling study centers from the completed single dose study to a Phase 2b multiple dose study of IPX203 in patients with advanced Parkinson’s disease.